New hope for pancreatic cancer: experimental drug OMO-103 enters human trials
NCT ID NCT06059001
First seen Jan 16, 2026 · Last updated Apr 25, 2026 · Updated 15 times
Summary
This early-stage trial tests an experimental drug called OMO-103, which targets a cancer-driving protein called MYC, combined with standard chemotherapy in 26 people with metastatic pancreatic cancer. The main goals are to check safety and how well the body handles the drug, while also looking for signs of tumor shrinkage. Participants must not have had prior treatment for advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Gregorio Marañon
Madrid, Madrid, 28007, Spain
-
Hospital Miguel Servet
Zaragoza, Zaragoza, 5009, Spain
-
Hospital Regional Universitario de Málaga
Málaga, Spain, 29010, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital Vall d´Hebrón
Barcelona, Barcelona, 08035, Spain
-
ICO Hopsitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Conditions
Explore the condition pages connected to this study.